INO is collaborating with AZN on combination treatment with Imfinzi for second-line H&N cancer (#msg-131236136), and INO has its own phase-3 trial underway in cervical pre-cancer (#msg-132005083).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”